Poland
Tuberculosis profile
Population  2012 38 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.67 (0.64–0.7) 1.8 (1.7–1.8)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0.01–0.01)
Prevalence  (includes HIV+TB) 11 (4.2–20) 28 (11–53)
Incidence  (includes HIV+TB) 8.1 (7.1–9.2) 21 (19–24)
Incidence (HIV+TB only) 0.032 (0.028–0.037) 0.08 (0.07–0.1)
Case detection, all forms (%) 87 (77–99)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 2 433 (37) Relapse 389 (44)
Smear-negative 3 371 (51) Treatment after failure 0 (0)
Smear-unknown / not done 358 (5) Treatment after default 0 (0)
Extrapulmonary 503 (8) Other 488 (56)
Other 0 (0)      
Total new 6 665   Total retreatment 877  
           
Other (history unknown) 0        
Total new and relapse 7 054   Total cases notified 7 542  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.6 1.8 1.1
Age < 15 2 49 43
Laboratories 2012
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 10.6
Drug susceptibility testing (per 5 million population) 6.0
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 60   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 65  
Retreatment 54  
TB/HIV 2012 Number (%)
TB patients with known HIV status 26 (<1)
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.49 (0.3–0.76) 2.1 (1–3.6)
MDR-TB cases among notified pulmonary
TB cases
30 (18–47) 18 (9–32)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 4 118 (91%) 541 (62%) 4 659
Laboratory-confirmed MDR-TB cases 20 11 31
Patients started on MDR-TB treatment     31
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-20 Data: www.who.int/tb/data